<DOC>
	<DOCNO>NCT01115712</DOCNO>
	<brief_summary>The purpose study evaluate whether 30 mg pioglitazone administer daily 28 day healthy overweight obese subject lead significant change insulin sensitivity , measure set hyperinsulinemic euglycemic clamp</brief_summary>
	<brief_title>Effects Pioglitazone Insulin Sensitivity Healthy Overweight Obese Males ( MK-0000-170 )</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Subject BMI great 28 kg/m^2 less equal 38 kg/m^2 Subject nonsmoker and/or use nicotine nicotinecontaining product least approximately 6 month Subject willing avoid major dietary change duration study Subject history diabetes ( Type 1 , Type 2 steroidinduced ) Subject history hypersensitivity pioglitazone thiazolidinediones Subject history liver disease , nonalcoholic fatty liver disease nonalcoholic steatohepatitis Subject history congestive heart failure Subject active past history atherosclerotic heart disease , heart failure , osteoporosis , osteopenia , recurrent bone fracture , anemia Subject history stroke , chronic seizure , major neurological disorder Subject history clinically significant endocrine , gastrointestinal , cardiovascular , hematological renal abnormality diseases Subject history neoplastic disease within past 5 year</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>